Estradiol Cream: What a Compounded Prescription Involves

Key Takeaways

• Vaginal estradiol cream may ease moderate to severe dryness, irritation and pain during sex after menopause.
• A licensed pharmacy mixes your cream for you, at the strength your provider prescribes.
• Your provider starts with your health history and labs, then checks in with you every three months and adjusts your plan if needed.
• If you have a uterus, your provider will talk with you about whether you also need a progestin.

Menopause can bring changes that are hard to bring up, like dryness, irritation or discomfort during sex. In a US survey of 3,046 women after menopause who had these symptoms, 55% reported vaginal dryness and 44% reported pain during sex. A prescription estradiol cream may help with all three.

How Can Estradiol Cream Help?

It may ease moderate to severe dryness, irritation and pain during sex after menopause. The approved estradiol vaginal cream is used to treat moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, the clinical name for those changes.

Tell your provider which symptoms bother you most, and they'll check in on how those are changing as you go.

What Does Compounded Mean?

It means your cream is made for you. A licensed pharmacy mixes it for one patient, based on a valid prescription, at the strength your provider chooses, instead of taking it off a shelf. LIV works with licensed pharmacy partners to prepare it.

How Your Provider Tailors Your Prescription

It starts with getting to know you. A licensed provider looks at your health history, your symptoms and your lab results, then decides whether estradiol cream is right for you.

If it is, your provider writes your prescription. It covers three things: the cream's strength (how much estradiol is in each gram), how much you apply and how often. How much your body absorbs depends on all three, so your instructions are written for you.

From there, your provider checks in with you every three months. You'll repeat your labs each time, and your provider looks at how you're feeling and what your results show, then adjusts your plan if needed.

Get started with estradiol cream

Staying Safe Between Check-Ins

Between check-ins, keep your provider in the loop:

• If side effects come up: let your provider know. Side effects listed on the label include breast tenderness, spotting, nausea and irritation where you apply the cream.
• If you have a uterus: your provider will talk with you about whether you need a progestin.

Let your provider know about any new vaginal bleeding or breast changes, and check with them before changing how much you use, how often or where.

Questions to Bring to Your Evaluation

A few questions worth asking:

• Which of my symptoms is this meant to help, and how will we know it's working?
• What do my labs show, and what would change my plan?
• Do I need a progestin too?

When you're ready, getting started with estradiol cream begins with an evaluation, where a licensed provider talks through your history and symptoms with you.

Related reading: The 2026 hormone therapy labeling change · Progesterone alongside estrogen

Frequently Asked Questions

What did studies of estradiol cream find?

In one study, women whose most bothersome symptom was dryness reported less dryness by week 4 than with a plain cream. In another, sexually active women whose main concern was pain during sex reported less painful sex by week 8. Both tested a very low-strength cream (0.003%), not a compounded cream, and results varied, so your provider will check in on how you're doing.

Is compounded estradiol cream FDA-approved?

Compounded medicines aren't FDA-approved, and the FDA doesn't review their safety, effectiveness or quality before they're marketed. It doesn't come with FDA-approved prescribing information of its own, so follow the directions on your prescription and the pharmacy label that comes with your cream.

What does the boxed warning on estradiol cream say?

The approved estradiol vaginal cream label carries a boxed warning. A boxed warning is printed in a box at the start of a prescription label and covers its most serious risks. It says that in a woman with a uterus, estrogen used alone raises the risk of endometrial cancer, and that adding a progestin has been shown to lower the chance of the uterine lining thickening. It also lists cardiovascular disorders, breast cancer and probable dementia, based on large studies of daily estrogen pills. In November 2025, the FDA asked manufacturers to remove all of these statements from the boxed warning on vaginal estrogen products, and many labels, including this one, haven't been updated yet. The label also asks that bleeding that keeps happening or comes back be checked, so tell your provider if it does.

Who shouldn't use estradiol cream?

Your provider reviews your history first. The approved estradiol cream label says estrogen isn't for women with unexplained genital bleeding, breast cancer now, in the past or suspected, another known or suspected estrogen-dependent cancer, a current or past blood clot, stroke or heart attack, liver disease, a clotting disorder, a severe allergic reaction to estradiol cream, or a known or suspected pregnancy.

Do I need progesterone with it?

If you have a uterus, ask about it at your first visit. Your provider will decide whether you need a progestin with your cream.

Can a vaginal cream affect the rest of my body?

It can. Some estrogen from vaginal cream may be absorbed, so your provider weighs the same safety information as for other estrogen treatments.

Why can't I get a dose before my evaluation?

Because your dose is written for you, from your own health history and labs. A cream's strength alone doesn't tell you how much your body absorbs, so your provider sets your plan once they've reviewed your results.

References

Archer, D. F., Kimble, T. D., Lin, F. D. Y., Battucci, S., Sniukiene, V., & Liu, J. H. (2018). A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. Journal of Women's Health, 27(3), 231-237. https://pubmed.ncbi.nlm.nih.gov/29193980/

Cornell Law School Legal Information Institute. (n.d.). 21 U.S. Code § 353a: Pharmacy compounding. Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/353a

Kingsberg, S. A., Wysocki, S., Magnus, L., & Krychman, M. L. (2013). Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. Journal of Sexual Medicine, 10(7), 1790-1799. https://pubmed.ncbi.nlm.nih.gov/23679050/

Kroll, R., Archer, D. F., Lin, Y., Sniukiene, V., & Liu, J. H. (2018). A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause, 25(2), 133-138. https://pubmed.ncbi.nlm.nih.gov/28926514/

Mylan Pharmaceuticals Inc. (2026). Estradiol Vaginal Cream USP, 0.01%: prescribing information. DailyMed, U.S. National Library of Medicine. Label updated February 15, 2026; read August 11, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98770987-b313-4f2a-9aac-db0ab2068cc6

U.S. Food and Drug Administration. (2025). FDA requests labeling changes related to safety information to clarify the benefit/risk considerations for menopausal hormone therapies. Drug Alerts and Statements, announced November 10, 2025; page content current as of February 12, 2026, read August 13, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations

U.S. Food and Drug Administration. (2026). Understanding the risks of compounded drugs. Human Drug Compounding. Content current as of June 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs

U.S. Food and Drug Administration. (2024). Frequently asked questions about labeling for prescription medicines. Content current as of April 1, 2024; read 2026-10-08. https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/frequently-asked-questions-about-labeling-prescription-medicines